Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $83.30 | Total: $416.50 |
| 1 | 10 | $70.56 | Total: $705.60 |
| 1 | 25 | $59.78 | Total: $1,494.50 |
| 1 | 50 | $50.96 | Total: $2,548.00 |
| 1 | 100 | $44.10 | Total: $4,410.00 |
Overview
AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions.
Chemical Properties
| Molecular Formula | C25H25F2N7O |
| Molecular Weight | 477.51 |
| CAS Numbers | 909561-15-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | NC(=O)CN1CCN(CC1)c1ccc(Nc2ncc3ccn(Cc4cc(F)cc(F)c4)c3n2)cc1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Nagashima S , Hondo T , Nagata H , et al. Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors[J]. Bioorg Med Chem, 2009, 17[19] 6926-6936.